Delivery Order SPE2DR25D9239-SPE2DR26FFCN3
Award Date 4/1/26
Potential Completion Date 4/22/26
Potential Value $39K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 20, 2026, for Perjeta 420 mg/14 mL vials, with a ceiling value of $29,434.86. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency-administered indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for Perjeta 420 mg/14 ml vials, with a ceiling value of $44,152.29. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 25, 2026, for $29,434.86 to supply Perjeta 420 mg/14 ml vials. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award indefinite delivery contract with a $499,999,999 ceiling through December 31, 2036. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 31, 2026, for Perjeta 420 mg/14 mL vials, with a ceiling value of $44,152.29. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 13, 2026, for Perjeta 420 mg/14 mL vials with a ceiling value of $29,434.86. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December 31, 2036. The parent contract authorizes firm fixed-price delivery orders for...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on January 6, 2026, for Perjeta 420 mg/14 mL vials, with a ceiling value of $29,434.86 and an ultimate completion date of January 28, 2026. This delivery order was issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical supply to Department of Defense military healthcare facilities...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $14,717.43 for supply of Perjeta 420 mg/14 mL vials under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is placed under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for Perjeta 420 mg/14 mL vials, with a ceiling value of $49,058.10. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling extending through December 31, 2036. The PPV-G GEN V program supports recurring pharmaceutical supply needs for Department...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for Perjeta 420 mg/14 ml vials with a ceiling value of $4,905.81, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The parent contract, SPE2DR, is a single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 17, 2026, for Perjeta 420 mg/14 ml vials, with a ceiling value of $58,869.72. The delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036. PPV-G GEN V authorizes DLA to issue firm fixed-price delivery orders for...